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Abstract
Schizophrenia is a genetically and clinically heterogeneous disorder. Genetic risk factors for the 
disorder may differ between the sexes or between multiply affected families compared to cases 
with no family history. Additionally, limited data support a genetic basis for variation in onset and 
severity, but specific loci have not been identified. We performed genome-wide association 
studies (GWAS) examining genetic influences on age at onset (AAO) and illness severity as well 
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as specific risk by sex or family history status using up to 2762 cases and 3187 controls from the 
International Schizophrenia Consortium (ISC).
Subjects with a family history of schizophrenia demonstrated a slightly lower average AAO that 
was not significant following multiple testing correction (p = .048), but no differences in illness 
severity were observed by family history status (p = .51). Consistent with prior reports, we 
observed earlier AAO (p = .005) and a more severe course of illness for men (p = .002). Family 
history positive analyses showed the greatest association with KIF5C (p = 1.96 × 10−8), however, 
genetic risk burden overall does not differ by family history. Separate association analyses for 
males and females revealed no significant sex-specific associations. The top GWAS hit for AAO 
was near the olfactory receptor gene OR2K2 (p = 1.52 × 10−7). Analyses of illness severity 
(episodic vs. continuous) implicated variation in ST18 (p = 8.24 × 10−7). These results confirm 
recognized demographic relationships but do not support a simplified genetic architecture for 
schizophrenia subtypes based on these variables.
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1. Introduction
Schizophrenia is a complex genetic disorder for which heterogeneity at the genetic and 
phenotypic levels has led to inconsistent results across several domains of research. The 
growing number of subjects in genome-wide association studies (GWAS) enhances power 
not only for detection of susceptibility loci, but also for numerous other investigations such 
as modifier locus detection or identifying more homogeneous disease subgroups. With 
heritability estimates of 64–81% (Sullivan et al., 2003; Lichtenstein et al., 2009), the genetic 
contribution to schizophrenia is substantial. As with other common complex disorders, the 
identification of specific, replicated common risk loci has required large-scale collaborative 
efforts including many thousands of subjects (Schizophrenia Psychiatric GWAS 
Consortium, 2011; Bergen and Petryshen, 2012). Genetic variation almost certainly impacts 
variability at the phenotypic level, and genetic factors contributing to variation within a 
disease may overlap with risk loci (susceptibility-modifiers) or could be independent of 
disease risk (true modifiers) (Fanous and Kendler, 2005).
Genome-wide association studies have not yet specifically addressed the familial/sporadic 
distinction. Unlike some other complex diseases, familial transmission of highly penetrant 
genetic risk factors in families has not been identified for schizophrenia. Several reports of 
differential genetic associations by sex have been published for schizophrenia, but few of 
these findings have been replicated, and to our knowledge, sex-specific genetic associations 
also remain untested in a GWAS framework.
In addition to the wide range of symptoms displayed by people with schizophrenia, several 
other features of this illness are highly variable. Schizophrenia may be diagnosed at any time 
from childhood through old age, and the severity of illness can range from mild with few 
psychotic episodes to severe and unremitting. Although similar numbers of males and 
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females are diagnosed with schizophrenia, males often have an earlier age at onset (AAO), 
increased illness severity, and less favorable prognoses (Lewine, 1980; Angermeyer and 
Kuhn, 1988; Hafner et al., 1993; Gorwood et al., 1995; Esterberg et al., 2010). Pubertal 
timing is reported to influence AAO in women suggesting sex-specific biological 
mechanisms influencing disease onset but not risk (Cohen et al., 1999). Heritability of AAO 
has been estimated at 33% indicating moderate genetic basis (Hare et al., 2010). Increased 
genetic risk loading has been related to earlier AAO for systemic lupus erythematosis (SLE), 
cancer, and Alzheimer’s disease and may also be true for schizophrenia (Beyer et al., 2005; 
Chen et al., 2009; Webb et al., 2011). Some individual genes have been associated with 
measures of severity in schizophrenia such as COMT (Wright et al., 2012), RGS2 and RGS5 
(Campbell et al., 2008), but the genetic relationship to course of illness has not yet been 
assessed on a genomic scale.
In this study, we explore the relationships between AAO, severity, sex, and family history, 
and investigate modifying genetic influences on age at onset (AAO) and severity as well as 




All participating adults were drawn from the International Schizophrenia Consortium (ISC); 
data collection, genotyping, and quality control steps have been previously described 
(International Schizophrenia Consortium, 2008; 2009). Analyses were restricted to subjects 
of European ancestry from the six sites with available phenotypic information (Aberdeen, 
Cardiff, Dublin, Edinburgh, Portugal, and London) resulting in up to 2762 cases and 3187 
controls remaining for analyses. All subjects gave written informed consent.
2.2. Phenotypes
AAO was defined as the age at diagnosis for schizophrenia. Cases were diagnosed according 
to DSM-IV (American Psychiatric Association, 2000) or ICD-10 (Janca et al., 1993) criteria 
as described in prior publications (International Schizophrenia Consortium, 2008; 2009). 
AAO values were log transformed by site to approximate a normal distribution. Subjects 
with any first degree relatives diagnosed with a psychotic disorder were deemed family 
history positive (FH+). Course of illness/severity was coded 1 (remitting) to 5 (severe, 
chronic) according to the Operational Criteria Checklist (OPCRIT) (McGuffin et al., 1991; 
Williams et al., 1996). Subjects from Edinburgh were removed from the severity analyses 
due to lack of variance for this measure. Genetic sex defined the male–female distinction. 
The number of subjects with available information for each analysis across all sites is shown 
in Table 1.
2.3. Phenotypic analysis methods
Two-tailed t-tests, conducted in R (R Development Core Team, 2012), were used to 
investigate 1) AAO differences by FH, 2) course by sex, 3) AAO by sex, and 4) AAO and 
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illness severity. Conservative adjustment presuming independence of the four tests 
conducted yielded a Bonferroni-corrected p-value threshold of .0125.
2.4. Genetic analyses
Most subjects were genotyped using Affymetrix 5.0 and 6.0 arrays, however, control 
subjects from London were genotyped using the Affymetrix 500k array. Single nucleotide 
polymorphism (SNP) calls were made using Birdsuite software (Korn et al., 2008). Quality 
control steps were fully reported previously (International Schizophrenia Consortium, 2009), 
but briefly: SNPs were excluded for low call rates or significantly different call rates 
between cases and controls, mapping to multiple locations, lack of variation (monomorphic), 
departure from Hardy–Weinberg equilibrium, or minor allele frequency <.01. Subjects were 
removed for low genotyping rates, having a second degree or closer relative in the dataset, 
population outlier status, or suspected sample contamination. Beagle software (Browning 
and Browning, 2007) was used to impute genotypes from HapMap2 (International HapMap 
Consortium, 2007) reference files containing ~2.4 million markers. Autosomal markers were 
imputed, and markers with high confidence scores (Info >.8) were retained for analyses.
2.4.1. GWAS analyses—All analyses were conducted in PLINK (Purcell et al., 2007) 
using linear regression (AAO) or logistic regression (sex, FH, course) and four 
multidimensional scaling covariates to control for genetic population variation. Sex was 
included as a covariate when not specifically tested. Most analyses were conducted by site 
and meta-analyzed. For severity, however, some sites contained few subjects with a mild, 
episodic course, therefore, subjects across all sites were analyzed together. Additionally, 
severity was dichotomized (mild 1–3 or severe 4–5) since this binary measure is less 
sensitive to potential rating differences across sites. After a Bonferroni correction to adjust 
the genome-wide association significance threshold (p < 5 × 10−8) for the six analyses 
performed, the significance threshold is p < 8.33 × 10−9.
We sought replication for our top AAO results in the Psychiatric Genomics Consortium 
schizophrenia data; removing the overlapping subjects yielded results from 5079 additional 
cases. Proxy SNPs with r2 > .8 were determined for markers not directly represented in both 
samples using the SNAP tool (Johnson et al., 2008). Family history and illness severity were 
not available measures for replication.
In addition to the separate GWAS analyses for AAO and sex, the genetic basis for the 
observed differences in AAO by sex was examined using the G × E test in PLINK which 
necessitated using the directly genotyped markers and no covariates.
2.4.2. Pathway analyses—To investigate whether nominally significant association 
signals cluster in genes involved in common biological pathways, top results from each 
association analysis were tested against Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways and synaptic functional gene-groups using INRICH (Lee et al., 2012). 
The KEGG database is a collection of molecular interaction and reaction network maps, 
manually defined and drawn by field experts. The synaptic gene database is comprised of 18 
groups of genes involved in synaptic functioning defined based on data mining, 
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experimentation, and experts’ curation (Lips et al., 2012). Details of the pathway analysis 
methods are located in the supplementary material, Appendix A.
2.4.3. Polygenic profile scoring—Polygenic scoring was used to evaluate whether FH+ 
subjects have increased genetic risk burden compared to FH- subjects and whether subjects 
with earlier AAO have increased genetic risk loading compared to later onset subjects. 
Scoring was conducted for each group separately using a Swedish schizophrenia dataset 
(2111 cases, 2535 controls) as the discovery sample (Bergen et al., 2012; International 
Schizophrenia Consortium, 2009). To implement this method, SNPs are weighted on the 
basis of the strength of their association (e.g. log OR) in a discovery sample, and these 
weights are applied to the SNPs in a target sample and aggregated to yield polygenic profiles 
scores for each individual. Quantitative scores were calculated for each subject based on the 
pT (p-value threshold), the proportion of SNPs with p-values <pT in the discovery sample. 
For each SNP set defined by pT, we calculated the proportion of variance explained (R2) by 
subtracting the Nagelkerke’s R2 attributable to ancestry covariates alone from the R2 for 
polygenic scores plus covariates (International Schizophrenia Consortium, 2009). Sample 
size is one determinant of the proportion of variance explained in polygenic scoring. 
Therefore, a random subset of the FH-sample was selected to be the same size as the FH+ 
sample. We also tested for possible differences in polygenic risk for early and late AAO by 
dividing the ISC (target set) cases into similarly-sized early (AAO ≤ 21, N = 1100) and late 
(AAO > 21, N = 1283) groups. T-tests were then performed for the resulting scores between 
subgroups across each p-value threshold examined (.01, .05, .1, .2, .3, .4, and .5).
3. Results
3.1. Phenotypic analysis results
We observed later average AAO in women (24.7 yrs) compared with men (23.7 yrs; t = 
−2.80, p = .005) and a more severe course of illness for men (t = 3.15, p = .002). Regardless 
of sex, a lower AAO was significantly related to a more severe disease course (t = −3.90, p 
= 9.93 × 10−5). Family history positive subjects demonstrated a lower average AAO (t = 
1.98, p = .048), but this was not significant following multiple testing correction. There were 
no significant differences in illness severity between family history groups (t = −.66, p = .
51).
3.2. Genetic results
3.2.1. GWAS results—Top results for all GWAS analyses are shown in Table 2. The 
strongest association signal for AAO analyses (rs11999864, p = 1.52 × 10−7) spanned two 
genes: an olfactory receptor, OR2K2, and a scaffolding protein, KIAA0368. We also 
investigated the top loci for our AAO analyses in the Psychiatric Genomics Consortium 
results. Restricting analyses to the samples not overlapping with this study and markers with 
r2 > .8 yielded no additional support for the loci identified by this study.
Analyses of disease severity highlighted variation near the ST18 gene as showing the 
greatest difference between subjects with a relatively mild episodic course compared to 
subjects with severe, chronic forms of illness (rs12548481, p = 8.24 × 10−7). This gene 
Bergen et al. Page 5













encodes a siRNA which is most highly expressed in brain and regulates apoptotic and 
inflammatory pathways (Yang et al., 2008).
In the sex-specific GWAS, the top result for the female-only analyses (rs17115481, p = 1.90 
× 10−6) also extended across two genes, FAM114A2, a brain expressed gene, and MFAP3, a 
microfibrillar associated protein. The male-specific analyses yielded the strongest signal in 
JMJD2C (rs7037878, p = 8.07 × 10−7), a histone demethylase which regulates androgen 
receptor function (Wissmann et al., 2007).
The AAO by sex test implicated variation in the GATA5 gene (rs6121620, 6.54 × 10−7). The 
strength of the association signal for this SNP is fairly similar in males and females, but it is 
in different directions (males: beta = .052, p = 1.33 × 10−5; females: beta = −.073, p = 4.76 × 
10−4). This gene has known functions in cardiac and smooth muscle, but its role in the brain 
is not yet known.
In the FH+ analyses, a strong, but not significant, signal (rs10929935, p = 1.96 × 10−8) 
spanned two genes: KIF5C, a microtubule-associated protein involved in organelle 
transport, and LYPD6B which is brain expressed but otherwise uncharacterized. Family 
history negative results revealed the strongest association signal in PTBP2 (rs11165690, p = 
9.96 × 10−8), a regulator of exon splicing and neuronal precursor cell differentiation.
3.2.2. Pathway analysis results—Two pathways from the synaptic database and none 
from KEGG remained significant following correction for all pathways tested within each 
set of association results (Supplementary Tables 1A–D). The “neurotransmitter metabolism” 
set was significantly enriched in the FH+ analyses (p = .045), and “intracellular signal 
transduction” was significant in the AAO results (p = .023). For the FH−, severity, male-
only, and female-only results, no pathways were significantly enriched.
3.2.3. Polygenic profile scoring results—FH+ and FH− groups showed no significant 
differences at any p-value threshold tested. Similarly, subjects with AAO ≤ 21 did not show 
increased polygenic risk burden (Supplementary Table 2).
4. Discussion
We tested genome-wide genotype data for association with AAO and severity of 
schizophrenia and whether differences in genetic risk factors were evident between FH+ and 
FH− groups or between males and females. Aside from one study of AAO (Wang et al., 
2011), these measures have been untested in a GWAS framework. Although results did not 
surpass genome-wide thresholds of significance, several strong association signals were 
observed.
The strongest association signal for the AAO genetic analyses (rs11999864, p = 8.85 × 10−7) 
did not show association in the main case–control analyses (p = .96) indicating potential 
modifier properties at this locus rather than susceptibility-modifier influences. Attempts to 
replicate the top loci for our AAO analyses in the Psychiatric Genomics Consortium yielded 
no additional support. The prior GWAS of AAO in a European–American sample reported 
association signals at 8q24.22, 4q25 in COL25A1, and 4p16.1 near RAF1P1 (Wang et al., 
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2011). Results for two of the reported SNPs in these regions were available in the present 
study, but failed to support association at these loci (rs7819815 at 8q24.22, p = .103; 
rs17407555 at 4p16.1, p = .616).
Early AAO could be due to modifying genetic or environmental influences or increased 
number or penetrance of genetic risk factors. A test of polygenic risk burden between early 
and late onset groups, divided at an AAO of 21, revealed no significant differences, 
suggesting that increased genetic risk due to common variants is not a major contributor to 
variation in onset timing. It is possible, however, that defining early and late onset 
differently could alter the results. Differential onset timing by sex may be mediated by 
GATA5, but the mechanism by which this might occur is not immediately clear pending 
elucidation of the role of this gene in the brain.
Next, we conducted association analyses of disease severity. Here, the marker showing the 
greatest association was, rs12548481 (p = 8.24 × 10−7), but this marker showed no 
association in the main case–control results (p = .86). As in the AAO results, this points 
toward possible modifying properties without affecting risk per se. The regulatory functions 
of the nearest gene, ST18, on inflammation and apoptotic pathways may hold clues to the 
mechanism by which illness severity is genetically mediated.
Although men and women exhibit differences in the presentation of schizophrenia, the 
similar rates of disease between the sexes do not suggest the presence of sex-specific risk 
factors. However, some distinct genetic risk loci are possible, and the top hit in the male-
only association analyses, JMJD2C (p = 8.07 × 10−7), might be considered a plausible 
candidate considering its prior association to autism spectrum disorders which are 
predominantly diagnosed in males and share some genetic and phenotypic features with 
schizophrenia (Kantojarvi et al., 2010). In Psychiatric Genomics Consortium schizophrenia 
analyses, including the ISC samples, this marker showed no evidence of association in male-
only GWAS results (p = .314; Stephan Ripke, personal communication).
We also considered family history as a potential stratifying variable. Under some disease 
models, FH+ subjects would be expected to have increased genetic risk burden compared to 
subjects without a family history of disease, however, we did not detect any differences in 
polygenic risk scores between these groups. The familial–sporadic distinction is fraught with 
problems for highly polygenic disorders such as schizophrenia (Kendler, 1987). Most 
“sporadic” cases actually have inherited genetic risk factors circulating in their families 
(Yang et al., 2010). Nevertheless, family history status may offer some utility. Having a 
close relative with schizophrenia is currently the best predictor of this diagnosis. 
Furthermore, some genetic risk factors may be related to family history status. For example, 
single nucleotide de novo mutations appear enriched in sporadic cases of schizophrenia (Xu 
et al., 2011), and the CNVs previously associated with this illness are far more likely to arise 
de novo (Rees et al., 2011).
Uncovering the mechanisms by which genetic changes exert their behavioral effects is vital 
to understanding schizophrenia etiology and pathology. To that end, the pathway analyses 
revealing “intracellular signal transduction” as modulating AAO offer some insight. 
Bergen et al. Page 7













Interestingly, one of the top genes driving the significance of this pathway, RYR2, encodes a 
calcium channel and was also a top hit in the prior GWAS of AAO for the female-only and 
AAO × gender analyses (Wang et al., 2011). The “neurotransmitter metabolism” pathway, 
significant for the FH+ analyses, was driven by signals in several neurotransmitter systems.
We confirmed previously reported relationships for four widely-studied clinical variables of 
schizophrenia: AAO, severity, sex and family history. Earlier AAO and more severe disease 
course were observed in male subjects, and for all subjects, earlier AAO was associated with 
increased severity. A link between early-onset illness and increased severity has been 
observed for several psychiatric conditions such as obsessive compulsive disorder,(Taylor, 
2011) bipolar disorder (Leverich et al., 2007), alcoholism (Hingson et al., 2006), and 
schizophrenia (Rabinowitz et al., 2006). A slightly lower AAO for FH+ subjects was not 
significant following correction for multiple tests, and no difference in disease severity was 
detected between FH+ and FH− groups. In a meta-analysis of 12 studies, earlier AAO in FH 
+ subjects was observed (Esterberg et al., 2010), and several explanations for this 
relationship are possible. For example, an increase in genetic risk in familial cases could 
precipitate earlier onset. Alternatively, the emotional distress of having an affected family 
member could lead to an earlier psychotic break in susceptible individuals, or familial 
awareness of this disease could facilitate recognition of prodromal symptoms and expedite 
diagnosis.
In conclusion, we replicated prior observations between the variables under investigation, 
but no significant results emerged from the GWAS of AAO, severity or disease associations 
by FH or sex. For AAO and severity, greater power from larger sample sizes may yield 
significant results since these are almost certainly genetically mediated to some extent. Since 
illness severity may increase over time, duration of illness should be taken into account 
when possible. In a highly polygenic disorder such as schizophrenia, the familial/sporadic 
dichotomy has little meaning since most “sporadic” cases will have genetic risk factors 
circulating in their families. Sex-specific genetic risk factors for schizophrenia are 
theoretically possible, however, the lack of significant results by sex in this study supports 
the idea that no strong sex-specific genetic risk factors exist for schizophrenia. Therefore, a 
simplified genetic architecture for schizophrenia predicated on subgrouping by FH or sex is 
not supported.
With the exception of one GWAS of AAO in schizophrenia, this is the first reported study of 
genetic associations for these characteristics in schizophrenia on this scale, and additional 
work remains to be done. For example, further explorations of whether the proportion of 
variance explained by common SNPs depends on FH, age of onset or gender would be 
useful. Environmental influences modifying the manifestation or risk for schizophrenia also 
need to be incorporated into investigations of heterogeneity. Furthermore, distinct modifying 
influences – genetic and environmental – may exist in different populations, and exploring 
these questions in other samples would be a worthwhile endeavor. Interventional efforts 
delaying onset or reducing the severity of schizophrenia could profoundly impact the lives 
and families of individuals with this disorder. Since the vast heterogeneity observed in 
schizophrenia is at least partially genetically mediated, a better understanding of the specific 
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genetic factors impacting this variability is a vital step in developing new prevention and 
treatment strategies.
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